194928-67-1

Upstream product

• 141-82-2 malonic acid 
• 58287-76-6 4-(N,N-Dimethylcarbamoyl)benzaldehyde 
• 619-66-9 4-Carboxybenzaldehyde 
• 16173-52-7 4-formylbenzoyl chloride 
• 215258-27-8 (E)-methyl 3-(4-(dimethylcarbamoyl)phenyl)acrylate 

Downstream Products

• 215258-13-2 3-bromo-8-[2,6-dichloro-3-[N-[4-(dimethylcarbamoyl)cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylimidazo[1,2-a]pyridine 
• 683273-31-6 4-[(1E)-3-({2-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-2,4-dichloromethylanilino]-2-oxoethyl}amino)-3-oxo-1-propenyl]-N,N-dimethylbenzamide 
• 189268-90-4 4-{(1E)-3-[({1-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-2,4-dichlorophenyl]-1H-pyrrol-2-yl}methyl)amino]-3-oxo-1-propenyl}-N,N-dimethylbenzamide 
• 683273-33-8 2,6-dichloro-3-({[((2E)-3-{4-[(dimethylamino)carbonyl]phenyl}-2-propenoyl)amino]acetyl}(methyl)amino)benzyl methanesulfonate 

Relevant academic research and scientific papers

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 2. Overcoming the species difference between guinea pig and man

Recently we reported the identification of a series of 8-[[3-(N- acylglycyl-N-methylamino)-2,6-dichlorobenzyl]oxy]-3-halo-2-methytimidazo[1,2- α]pyridines as the first orally active non-peptide bradykinin (BK)B2 receptor antagonists (1-3). Thes